-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
First Public Notice of the Environmental Impact Assessment for the Green Development Project of Active Pharmaceutical Ingredients at Hebei Guolong Pharmaceutical Co., Ltd. of Shisiyao Group
Category:
发布时间：2021-08-27
【概要描述】
In accordance with the Measures for Public Participation in Environmental Impact Assessment (Ministerial Order No. 4, dated July 16, 2018), the project proponent shall, within seven working days after designating the entity responsible for preparing the environmental impact assessment report, disclose relevant information through an online platform.
I. Basic Project Information
1. Project Name: Green Development Project for Active Pharmaceutical Ingredients at Hebei Guolong Pharmaceutical Co., Ltd. of Shisiyao Group
2. Construction Address: South of Sanxia Road and West of Industrial Avenue, Shijiazhuang Economic and Technological Development Zone
3. Project Scope: The project involves the construction of a new workshop with a floor area of approximately 3,750 square meters, as well as production lines for 11 active pharmaceutical ingredients, including tenofovir alafenamide fumarate and linezolid, along with supporting logistics and utility facilities.
4. Project Scale: Annual production capacity of 16 tonnes for tenofovir alafenamide fumarate and linezolid combined, with an additional annual capacity of 2.43 tonnes for nine other pharmaceutical products.
II. Name and Contact Information of the Project Owner
Construction Entity Name: Hebei Guolong Pharmaceutical Co., Ltd.
Contact: Wei Xiaowei
Contact number: 18032935650
III. Name of the Unit Preparing the Environmental Impact Report
Hebei Jidu Environmental Protection Technology Co., Ltd.
IV. Online Link to the Public Opinion Form
Starting from the date of public notice, the general public may access the following link to download the Public Comments Form and submit their feedback: https://pan.baidu.com/s/1ohxnwAYjmpD9ascQ1V_oMw (Extraction code: n69n).
V. Methods and Channels for Public Submission of Comments
The public may contact the project developer by letter, fax, email, telephone, or other means.
Construction Entity Name: Hebei Guolong Pharmaceutical Co., Ltd.
Contact: Wei Xiaowei
Contact number: 18032935650
Fax: 0311-67107152
Email: 821736359@qq.com
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091